The Anti-Inflammatory Therapeutics Market is Becoming Attractive due to its Continuous Growth

Friday 21 October 2011, Amsterdam

The Anti-Inflammatory Therapeutics Market is Becoming Attractive due to its Continuous Growth

The anti-inflammatory therapeutics market accounted for $32.3 billion in 2002 from its seven major indications. From 2002, the market grew at a rate of 7.6% to $57.8 billion in 2010, and is forecast to grow at a rate of 5.8% during the forecast period, to produce revenues of $85.9 billion in 2017. This decrease from 7.6% to 5.8% will be due to patent expiries of some biologics and small molecules; these patent expiries will make an entry point for generics in the market, and their negative impact will be reversed by strong pipeline molecules that are currently in various phases of clinical trials.
 

The Anti-Inflammatory Therapeutics Market is one of the Major Parts of the Global Pharmaceutical Industry

The global anti-inflammatory therapeutics market in 2010 accounted for $65.8 billion, and had a growing trend which will continue during the forecast period. The anti-inflammatory therapeutics market is linked to seven diseases as major indications, which include respiratory inflammatory diseases (asthma and chronic obstructive pulmonary disease), arthritis (rheumatoid arthritis and osteoarthritis), multiple sclerosis, psoriasis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), spondyloarthropathies (ankylosing spondylitis and psoriatic arthritis), gout, and others (which includes the anti-inflammatory therapeutics market other than the seven major indications). The anti-inflammatory therapeutics market accounts for a share of 7.4% from global pharmaceutical revenues, and is expected to grow during the forecast period of seven years.    


Respiratory Diseases, Arthritis and Multiple Sclerosis Molecules Account for 77% of the Global Anti-Inflammatory Pipeline

The respiratory, arthritis and multiple sclerosis pipeline portfolios have 33%, 31% and 13% of the molecules across the different developmental stages, respectively. The number of programs in the regulatory filing, Phase III and Phase II stages of development accounted for approximately 49% of the total number of pipeline programs. This indicates that the imminent launch of these drugs could increase the anti-inflammatory therapeutics market value.

The arthritis market has a strong pipeline that will support the growth of this market, thereby attracting many pharmaceutical and biotechnological companies.

The entry of pipeline molecules will boost the anti-inflammatory therapeutics market, thereby bringing about further rises in the therapeutics market in the coming years. The rapid entry of new players and highly active pipeline will intensify competition.

The promising molecules have been detailed in section of “Profiles of Promising Molecules” of the report. They will boost the anti-inflammatory therapeutics market during the forecast period. The anti-inflammatory therapeutics market is expected to grow at a rate of 5.8% during the forecast period.


About this new market study:
This report also examines the global anti-inflammatory treatment usage patterns. In addition, the geographical distribution of anti-inflammatory therapies across the US, the top five countries in the European region, and Japan is also provided in the report. The report also includes insights into the anti-inflammatory R&D pipeline. The report provides an in-depth analysis of the top seven inflammatory therapeutic indications, which are respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these seven therapeutic indications. The report also explores the competitive landscape, including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving anti-inflammatory treatments is also presented.